ERBB2 and breast carcinoma: In human epidermal growth factor receptor 2 (HER2/neu, c-erbB2) positive breast cancer cells, STARD3 is associated with a poor prognosis, and lower levels of STARD3 increase cell death while reducing cell proliferation [80].